Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Short term Debt (2018 - 2024)

Neurocrine Biosciences (NBIX) has disclosed Short term Debt for 4 consecutive years, with $122.8 million as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Short term Debt changed N/A year-over-year to $122.8 million, compared with a TTM value of $122.8 million through Mar 2024, changed N/A, and an annual FY2023 reading of $170.1 million, changed N/A over the prior year.
  • Short term Debt was $122.8 million for Q1 2024 at Neurocrine Biosciences, down from $170.1 million in the prior quarter.
  • Across five years, Short term Debt topped out at $425.0 million in Q3 2020 and bottomed at $122.8 million in Q1 2024.
  • Average Short term Debt over 3 years is $246.2 million, with a median of $170.0 million recorded in 2023.